Schell Trevor L, Caldera Freddy
Department of Internal Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Gastroenterol Hepatol (N Y). 2024 Feb;20(2):88-97.
The COVID-19 pandemic introduced significant uncertainty regarding the care of patients with inflammatory bowel disease (IBD). Substantial research efforts have made progress in answering many of the questions that arose, but the constantly shifting paradigm of COVID-19-related research and recommendations has made it challenging for IBD clinicians to remain up-to-date. The goal of this article is to provide a concise and practical summary of the literature evaluating COVID-19 disease risk in addition to COVID-19 vaccine safety, immunogenicity, real-world effectiveness, and uptake among patients with IBD.
新冠疫情给炎症性肠病（IBD）患者的护理带来了极大的不确定性。大量研究工作在解答由此产生的许多问题方面取得了进展，但与新冠相关的研究和建议模式不断变化，使得IBD临床医生难以跟上最新进展。本文的目的是对评估新冠疾病风险以及新冠疫苗安全性、免疫原性、实际效果和IBD患者接种情况的文献进行简明实用的总结。
